arrow
Z

Ziad Younes

gastro one
H指数:37
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

354a: ONGOING PHASE 1B/2 TRIAL OF THE ALLOSTERIC MEK1/2 INHIBITOR REC-4881 AS MONOTHERAPY IN FAMILIAL ADENOMATOUS POLYPOSIS (FAP): PRELIMINARY SAFETY AND EFFICACY DATA

354a: REC-4881作为选择性MEK1/2变构抑制剂的单药治疗在家族性腺瘤性息肉病(FAP)中的Ib/II期临床试验:初步安全性和有效性数据

2025-07-030
PRE
Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials
2023-01-0111
OAAI
Quality of Care Program Reduces Unplanned Health Care Utilization in Patients With Inflammatory Bowel Disease
2021-12-0117
OA
Health Economic Impact of a Multicenter Quality-of-Care Initiative for Reducing Unplanned Healthcare Utilization Among Patients With Inflammatory Bowel Disease
2021-11-035
OA
Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH

包括Cilofexor和Firsocostat在内的联合疗法可桥接NASH引起的纤维化和肝硬化

2021-02-15185
PREAI
Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis
2021-01-01199
OAAI
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials
2020-07-01306
PREAI
Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension
2020-05-01111
OAAI
Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials
2019-08-19202
PREAI